Your browser is no longer supported. Please, upgrade your browser.
Settings
ILMN [NASD]
Illumina, Inc.
IndexS&P 500 P/E118.34 EPS (ttm)4.26 Insider Own0.30% Shs Outstand146.00M Perf Week2.52%
Market Cap73.06B Forward P/E69.90 EPS next Y7.22 Insider Trans-7.86% Shs Float145.62M Perf Month6.27%
Income630.00M PEG5.80 EPS next Q1.36 Inst Own92.70% Short Float1.63% Perf Quarter33.37%
Sales3.47B P/S21.04 EPS this Y-34.10% Inst Trans0.21% Short Ratio3.59 Perf Half Y20.09%
Book/sh33.71 P/B14.97 EPS next Y19.48% ROA8.10% Target Price406.44 Perf Year28.18%
Cash/sh31.98 P/C15.78 EPS next 5Y20.40% ROE13.30% 52W Range260.42 - 555.77 Perf YTD36.38%
Dividend- P/FCF82.09 EPS past 5Y7.40% ROI6.50% 52W High-9.21% Beta0.92
Dividend %- Quick Ratio4.20 Sales past 5Y7.90% Gross Margin67.60% 52W Low93.76% ATR10.51
Employees7800 Current Ratio4.40 Sales Q/Q27.20% Oper. Margin16.80% RSI (14)67.98 Volatility1.84% 2.40%
OptionableYes Debt/Eq0.44 EPS Q/Q-14.50% Profit Margin18.10% Rel Volume1.32 Prev Close498.42
ShortableYes LT Debt/Eq0.34 EarningsAug 05 AMC Payout0.00% Avg Volume663.32K Price504.60
Recom2.80 SMA204.60% SMA509.90% SMA20026.00% Volume876,490 Change1.24%
Jun-01-21Upgrade Evercore ISI Underperform → In-line $400
Mar-31-21Upgrade Canaccord Genuity Hold → Buy $445
Mar-31-21Downgrade Atlantic Equities Overweight → Neutral $390
Mar-03-21Initiated Barclays Underweight $325
Dec-22-20Upgrade Piper Sandler Neutral → Overweight $340 → $415
Dec-17-20Upgrade BTIG Research Neutral → Buy $410
Oct-13-20Downgrade Guggenheim Buy → Neutral
Sep-30-20Initiated Atlantic Equities Overweight $355
Sep-29-20Downgrade Wolfe Research Outperform → Peer Perform
Sep-22-20Downgrade UBS Buy → Neutral $390 → $285
Sep-22-20Downgrade Stifel Buy → Hold $380 → $280
Sep-21-20Upgrade Guggenheim Neutral → Buy $345
Sep-21-20Downgrade JP Morgan Overweight → Neutral $390 → $280
Sep-09-20Initiated Morgan Stanley Equal-Weight $400
Aug-07-20Downgrade Piper Sandler Overweight → Neutral $356 → $340
Aug-07-20Downgrade Evercore ISI In-line → Underperform $310
Jul-07-20Downgrade Guggenheim Buy → Neutral
Apr-24-20Downgrade Citigroup Buy → Neutral $250 → $320
Apr-21-20Downgrade Robert W. Baird Outperform → Neutral $310
Jan-08-20Initiated Wells Fargo Underweight $300
Aug-04-21 12:52PM  
10:39AM  
Aug-03-21 09:30PM  
Jul-30-21 06:35AM  
Jul-29-21 03:05PM  
06:55AM  
Jul-28-21 06:30PM  
Jul-26-21 08:50AM  
Jul-23-21 12:28PM  
06:00AM  
Jul-22-21 12:49PM  
12:39PM  
12:31PM  
12:19PM  
12:19PM  
12:15PM  
Jul-21-21 12:45PM  
03:21AM  
Jul-20-21 12:10PM  
12:00PM  
Jul-19-21 07:07AM  
Jul-14-21 11:50AM  
07:31AM  
Jul-13-21 08:00PM  
05:00PM  
03:18PM  
Jul-08-21 04:44PM  
Jul-03-21 09:00AM  
Jun-30-21 11:30AM  
Jun-28-21 01:12PM  
Jun-25-21 11:58AM  
Jun-22-21 10:03AM  
Jun-18-21 08:22PM  
04:13PM  
Jun-17-21 10:36AM  
05:34AM  
Jun-12-21 06:10AM  
Jun-10-21 08:00AM  
06:43AM  
Jun-09-21 09:08AM  
06:47AM  
Jun-04-21 12:55PM  
09:09AM  
08:37AM  
Jun-01-21 07:40AM  
03:05AM  
May-31-21 08:00PM  
04:00PM  
10:45AM  
07:24AM  
May-29-21 07:07AM  
06:45AM  
May-28-21 01:27PM  
09:31AM  
May-27-21 05:00PM  
11:31AM  
05:53AM  
May-25-21 11:30AM  
May-22-21 04:50AM  
May-20-21 07:27AM  
May-19-21 08:04AM  
07:22AM  
May-18-21 10:27AM  
May-17-21 04:05PM  
02:45PM  
10:00AM  
08:05AM  
07:24AM  
May-13-21 06:16AM  
05:30AM  
May-11-21 10:59AM  
09:35AM  
07:50AM  
May-10-21 02:25PM  
May-07-21 08:59AM  
May-06-21 08:57AM  
08:55AM  
07:24AM  
06:14AM  
May-05-21 08:29AM  
08:26AM  
08:25AM  
08:24AM  
07:01AM  
May-04-21 06:09PM  
11:59AM  
11:27AM  
08:16AM  
May-03-21 04:05PM  
09:24AM  
Apr-30-21 02:00PM  
08:46AM  
Apr-29-21 05:30PM  
09:05AM  
Apr-28-21 08:00PM  
09:39AM  
09:05AM  
06:04AM  
12:00AM  
Apr-27-21 05:37PM  
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TOUSI SUSAN HSVP, Chief Commercial OfficerJul 28Sale486.41300145,92342,743Jul 29 04:34 PM
Dadswell CharlesSVP & General CounselJul 22Sale482.23314151,4205,576Jul 26 04:57 PM
Aravanis AlexanderSVP, Chief Technology OfficerJul 07Sale477.59539257,4214,679Jul 07 06:26 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerJun 28Sale478.95300143,68543,043Jun 30 05:27 PM
Dadswell CharlesSVP & General CounselJun 22Sale461.01314144,7575,890Jun 24 05:41 PM
Febbo Phillip G.SVP Chief Medical OfficerJun 11Sale447.591,000447,5884,461Jun 14 05:50 PM
DORSA CAROLINEDirectorJun 10Sale450.001,000450,0008,501Jun 14 05:48 PM
Dadswell CharlesSVP & General CounselMay 24Sale403.04314126,5556,204May 26 04:50 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerMay 20Sale400.00500200,00043,343May 24 04:43 PM
FLATLEY JAY TDirectorMay 18Sale379.534,0001,518,120148,933May 20 04:51 PM
TOUSI SUSAN HSVP Product DevelopmentMay 05Sale381.88300114,56443,843May 06 05:26 PM
FLATLEY JAY TDirectorMay 04Sale384.154,0001,536,600152,933May 06 05:21 PM
Dadswell CharlesSVP & General CounselApr 22Sale402.02314126,2346,518Apr 26 07:52 PM
FLATLEY JAY TDirectorApr 20Sale401.834,0001,607,320156,933Apr 22 05:05 PM
FLATLEY JAY TDirectorApr 06Sale423.444,0001,693,740160,933Apr 07 04:41 PM
TOUSI SUSAN HSVP Product DevelopmentApr 06Sale423.44500211,71844,143Apr 07 04:34 PM
TOUSI SUSAN HSVP Product DevelopmentApr 05Sale386.03300115,80944,643Apr 07 04:34 PM
Dadswell CharlesSVP & General CounselMar 22Sale416.24314130,6996,832Mar 24 04:41 PM
FLATLEY JAY TDirectorMar 16Sale421.064,0001,684,240164,933Mar 18 07:20 PM
TOUSI SUSAN HSVP Product DevelopmentMar 05Sale402.24800321,79244,943Mar 09 05:29 PM
FLATLEY JAY TDirectorMar 02Sale444.614,0001,778,440168,933Mar 04 05:04 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerFeb 18Sale486.75666324,1761,538Feb 22 05:11 PM
TOUSI SUSAN HSVP Product DevelopmentFeb 17Option Exercise0.006,306048,921Feb 18 04:52 PM
SAMAD SAMSVP and CFOFeb 17Option Exercise0.004,37909,355Feb 18 04:51 PM
RAGUSA ROBERT PSVP, Global Quality & OpsFeb 17Option Exercise0.006,306012,795Feb 18 04:49 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerFeb 17Option Exercise0.0093502,576Feb 18 04:47 PM
Hoyt Aimee LSVP, Chief People OfficerFeb 17Option Exercise0.004,62508,873Feb 18 04:45 PM
Febbo Phillip G.SVP Chief Medical OfficerFeb 17Option Exercise0.003,17307,046Feb 18 04:44 PM
deSouza Francis APresident and CEOFeb 17Option Exercise0.0024,521085,934Feb 18 04:42 PM
Dadswell CharlesSVP & General CounselFeb 17Option Exercise0.003,50308,781Feb 18 04:41 PM
FLATLEY JAY TDirectorFeb 16Sale495.09500247,5433,500Feb 18 07:08 PM
FLATLEY JAY TDirectorFeb 16Sale505.264,0002,021,040172,933Feb 18 07:08 PM
TOUSI SUSAN HSVP Product DevelopmentFeb 05Sale431.90800345,52039,713Feb 09 04:48 PM
Hoyt Aimee LSVP, Chief People OfficerFeb 02Sale444.845725,3562,359Feb 03 05:00 PM
FLATLEY JAY TDirectorFeb 02Sale444.844,0001,779,360176,933Feb 03 04:58 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerFeb 02Sale444.847232,0281,538Feb 03 04:57 PM
deSouza Francis APresident and CEOFeb 01Sale439.783,0001,319,33052,603Feb 03 04:56 PM
TOUSI SUSAN HSVP Product DevelopmentJan 20Sale400.002,5001,000,00040,447Jan 21 04:40 PM
FLATLEY JAY TDirectorJan 19Sale382.484,0001,529,920180,933Jan 21 04:38 PM
Hoyt Aimee LSVP, Chief People OfficerJan 11Sale379.65271102,8852,359Jan 12 04:41 PM
TOUSI SUSAN HSVP Product DevelopmentJan 05Sale365.27300109,58142,947Jan 06 07:20 PM
FLATLEY JAY TDirectorJan 05Sale365.274,0001,461,080184,933Jan 06 07:19 PM
deSouza Francis APresident and CEOJan 04Sale370.513,0001,111,53755,540Jan 06 07:17 PM
FLATLEY JAY TDirectorDec 15Sale348.844,0001,395,360188,933Dec 16 06:07 PM
Hoyt Aimee LSVP, Chief People OfficerDec 14Sale345.00354122,1302,744Dec 16 06:05 PM
Ronaghi MostafaSVP, Entrepreneurial DevlopmtDec 10Sale338.585,0001,692,92280,162Dec 14 04:12 PM
TOUSI SUSAN HSVP Product DevelopmentDec 07Sale349.34300104,80343,247Dec 08 05:34 PM
TOUSI SUSAN HSVP Product DevelopmentDec 04Sale350.0020070,00043,547Dec 08 05:34 PM
Dadswell CharlesSVP & General CounselDec 01Sale323.861,694548,6193,460Dec 02 05:48 PM
deSouza Francis APresident and CEODec 01Sale327.953,000983,85158,540Dec 02 05:45 PM
TOUSI SUSAN HSVP Product DevelopmentDec 01Sale325.0010032,50043,747Dec 02 05:41 PM
FLATLEY JAY TDirectorDec 01Sale323.904,0001,295,590192,933Dec 02 05:37 PM
RAGUSA ROBERT PSVP, Global Quality & OpsNov 30Sale314.822,890909,8274,092Dec 02 05:34 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerNov 18Sale300.0021865,4001,538Nov 19 04:16 PM
FLATLEY JAY TDirectorNov 17Sale297.163,000891,470196,933Nov 19 04:18 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerNov 06Sale310.1031296,7511,872Nov 09 05:40 PM
Hoyt Aimee LSVP, Chief People OfficerNov 06Sale310.1021566,6723,098Nov 09 05:39 PM
Febbo Phillip G.SVP Chief Medical OfficerNov 06Sale310.1015548,0662,143Nov 09 05:35 PM
FLATLEY JAY TDirectorNov 03Sale297.343,000892,010199,933Nov 04 04:43 PM
deSouza Francis APresident and CEONov 02Sale300.283,000900,85265,840Nov 04 04:39 PM
Dadswell CharlesSVP & General CounselNov 02Sale298.0012136,0586,036Nov 04 04:34 PM
FLATLEY JAY TDirectorOct 20Sale321.714,0001,286,860202,933Oct 22 03:47 PM
TOUSI SUSAN HSVP Product DevelopmentOct 12Sale350.0020070,00044,968Oct 14 04:07 PM
TOUSI SUSAN HSVP Product DevelopmentOct 07Sale325.0010032,50045,168Oct 08 05:21 PM
FLATLEY JAY TDirectorOct 07Sale324.011,000324,010206,933Oct 08 05:18 PM
FLATLEY JAY TDirectorOct 06Sale317.793,000953,370207,933Oct 07 04:49 PM
deSouza Francis APresident and CEOOct 01Sale308.783,000926,33168,840Oct 05 05:14 PM
Dadswell CharlesSVP & General CounselOct 01Sale312.8212137,8516,157Oct 05 05:11 PM
FLATLEY JAY TDirectorSep 15Sale355.224,0001,420,880210,933Sep 17 04:59 PM
TOUSI SUSAN HSVP Product DevelopmentSep 09Sale350.0020070,00045,268Sep 10 04:49 PM
TOUSI SUSAN HSVP Product DevelopmentSep 08Sale336.0010033,60045,468Sep 10 04:49 PM
Van Oene MarkSVP Chief Commercial OfficerSep 01Sale355.13625221,95317,648Sep 02 07:52 PM
deSouza Francis APresident and CEOSep 01Sale352.323,0001,056,96471,840Sep 02 07:49 PM
Dadswell CharlesSVP & General CounselSep 01Sale355.351,687599,4756,278Sep 02 07:45 PM
FLATLEY JAY TDirectorSep 01Sale355.354,0001,421,400214,933Sep 02 07:35 PM
RAGUSA ROBERT PSVP, Global Quality & OpsAug 31Sale355.185,0001,775,9078,103Sep 02 07:29 PM
FLATLEY JAY TDirectorAug 18Sale354.034,0001,416,120218,933Aug 20 05:14 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerAug 10Sale357.011,856662,6112,350Aug 12 04:32 PM
TOUSI SUSAN HSVP Product DevelopmentAug 05Sale399.02800319,22045,568Aug 06 04:21 PM